<DOC>
	<DOCNO>NCT00233662</DOCNO>
	<brief_summary>The purpose study determine whether repeat course alefacept , administer intramuscularly , safe give chronic plaque psoriasis patient receive standard dermatology treatment .</brief_summary>
	<brief_title>Safety Tolerability Repeat Courses IM Alefacept</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Written inform consent . At least 16 year age . Diagnosed chronic plaque psoriasis require systemic therapy . CD4+ lymphocyte count low limit normal Covance Central Laboratory Services , Inc. , unless stable dose prednisone ( count must 300 cells/mm3 ) . Unstable erthrodermic pustular psoriasis . Diagnosis guttate psoriasis . Serious local infection systemic infection within 3 month prior first dose alefacept . Positive HIV antibody . Known invasive malignancy within 5 year enrollment . Patients history treat squamous cell and/or basal cell carcinoma limit skin exclude . Evidence active tuberculosis . Current treatment active tuberculosis tuberculosis prophylaxis . Female patient unwilling practice effective contraception define investigator . Female patient pregnant breastfeeding . Current enrollment investigational drug study . Previous participation study previous alefacept study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
</DOC>